TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$50.39
−0.36%Year over year
Reported trailing growth
- Revenue
- +77.1%
- EBITDA
- +105.4%
- EBIT
- +76.5%
- EPS
- +77.9%
- Free cash flow
- +135.5%
- Operating cash flow
- +180.3%
Forward estimates
Based on analyst estimates
- Revenue
- +77.0%
- EBITDA
- +7102.9%
- EPS
- +686.0%
Three-year CAGR
- Revenue
- +64.9%
- EBITDA
- +108.4%
- EBIT
- +80.6%
- Net income
- +92.1%
- EPS
- +86.3%
- Free cash flow
- +94.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026